394 related articles for article (PubMed ID: 7912834)
1. Somatostatin analogs for diagnosis and treatment of cancer.
Weckbecker G; Raulf F; Stolz B; Bruns C
Pharmacol Ther; 1993 Nov; 60(2):245-64. PubMed ID: 7912834
[TBL] [Abstract][Full Text] [Related]
2. The significance of somatostatin analogues in the antiproliferative treatment of carcinomas.
Kath R; Höffken K
Recent Results Cancer Res; 2000; 153():23-43. PubMed ID: 10626287
[TBL] [Abstract][Full Text] [Related]
3. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
4. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
Weckbecker G; Raulf F; Bodmer D; Bruns C
Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
[TBL] [Abstract][Full Text] [Related]
5. Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides.
Raynor K; Murphy WA; Coy DH; Taylor JE; Moreau JP; Yasuda K; Bell GI; Reisine T
Mol Pharmacol; 1993 Jun; 43(6):838-44. PubMed ID: 8100350
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
7. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin.
Afargan M; Janson ET; Gelerman G; Rosenfeld R; Ziv O; Karpov O; Wolf A; Bracha M; Shohat D; Liapakis G; Gilon C; Hoffman A; Stephensky D; Oberg K
Endocrinology; 2001 Jan; 142(1):477-86. PubMed ID: 11145612
[TBL] [Abstract][Full Text] [Related]
8. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.
Bruns C; Lewis I; Briner U; Meno-Tetang G; Weckbecker G
Eur J Endocrinol; 2002 May; 146(5):707-16. PubMed ID: 11980628
[TBL] [Abstract][Full Text] [Related]
9. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes.
Jaquet P; Saveanu A; Gunz G; Fina F; Zamora AJ; Grino M; Culler MD; Moreau JP; Enjalbert A; Ouafik LH
J Clin Endocrinol Metab; 2000 Feb; 85(2):781-92. PubMed ID: 10690891
[TBL] [Abstract][Full Text] [Related]
10. Characterization of cloned somatostatin receptors SSTR4 and SSTR5.
Raynor K; O'Carroll AM; Kong H; Yasuda K; Mahan LC; Bell GI; Reisine T
Mol Pharmacol; 1993 Aug; 44(2):385-92. PubMed ID: 8102785
[TBL] [Abstract][Full Text] [Related]
11. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
12. Novel heptapeptide somatostatin analog displays anti-tumor activity independent of effects on growth hormone secretion.
Murphy WA; Taylor JE; Moreau JP; Coy DH
Pept Res; 1989; 2(1):128-32. PubMed ID: 2577697
[TBL] [Abstract][Full Text] [Related]
13. Development of a selective agonist at the somatostatin receptor subtype sstr1.
Liapakis G; Hoeger C; Rivier J; Reisine T
J Pharmacol Exp Ther; 1996 Mar; 276(3):1089-94. PubMed ID: 8786539
[TBL] [Abstract][Full Text] [Related]
14. Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor.
Feuerbach D; Fehlmann D; Nunn C; Siehler S; Langenegger D; Bouhelal R; Seuwen K; Hoyer D
Neuropharmacology; 2000 Jun; 39(8):1451-62. PubMed ID: 10818261
[TBL] [Abstract][Full Text] [Related]
15. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
Siehler S; Seuwen K; Hoyer D
Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
[TBL] [Abstract][Full Text] [Related]
16. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs.
Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L
Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
Shimon I
Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
[TBL] [Abstract][Full Text] [Related]
19. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
Tulipano G; Bonfanti C; Milani G; Billeci B; Bollati A; Cozzi R; Maira G; Murphy WA; Poiesi C; Turazzi S; Giustina A
Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
[TBL] [Abstract][Full Text] [Related]
20. Characterization of cloned human somatostatin receptor SSTR5.
O'Carroll AM; Raynor K; Lolait SJ; Reisine T
Mol Pharmacol; 1994 Aug; 46(2):291-8. PubMed ID: 8078491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
